EORTC protocols in <font color="blue">prostatic_2</font> <font color="blue">cancer_2</font> <font color="blue">._2</font> An interim report . 
<br>
<br> Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in <font color="blue">previously_3</font> <font color="blue">untreated_4</font> <font color="blue">patients_5</font> <font color="blue">with_5</font> <font color="blue">prostatic_5</font> <font color="blue">cancer_5</font> <font color="blue">in_1</font> <font color="blue">order_1</font> to compare low dose Stilboestrol versus Cyproterone acetate versus Medroxyprogesterone acetate in the first trial , and Stilboestrol versus Estracyt in the second trial . Although the follow up is still short , no superiority of the other drugs over Stilboestrol had appeared so far with regard to either objective response or significant side effects apart from gynaecomastia . In the third trial , <font color="blue">patients_3</font> <font color="blue">with_3</font> <font color="blue">advanced_3</font> <font color="blue">disease_3</font> <font color="blue">no_2</font> <font color="blue">longer_2</font> <font color="blue">responsive_2</font> <font color="blue">to_2</font> <font color="blue">hormonal_2</font> <font color="blue">treatment_2</font> were randomized to either Adriamycin or Procarbazine . Toxicity and early death were particularly frequent in <font color="blue">Procarbazine_1</font> <font color="blue">treated_1</font> <font color="blue">patients_1</font> <font color="blue">,_1</font> whereas most patients progressed in both treatment groups .